EMEA-002066-PIP01-20 - paediatric investigation plan
talazoparib
PIPHuman
Key facts
- Invented name
- Talzenna
- Active Substance
- talazoparib
- Therapeutic area
- Oncology
- Decision number
- P/0224/2021
- PIP number
- EMEA-002066-PIP01-20
- Pharmaceutical form(s)
- Capsule, hard
- Condition(s) / indication(s)
- Treatment of Ewing sarcoma
- Route(s) of administration
- Oral use
- Contact for public enquiries
Pfizer Europe MA EEIG
E-mail: medical.information@pfizer.com
Tel. +44 1304646607- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date